<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001426</url>
  </required_header>
  <id_info>
    <org_study_id>950055</org_study_id>
    <secondary_id>95-C-0055</secondary_id>
    <nct_id>NCT00001426</nct_id>
    <nct_alias>NCT00019045</nct_alias>
  </id_info>
  <brief_title>A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer</brief_title>
  <official_title>A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human&#xD;
      ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for&#xD;
      8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration&#xD;
      causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and&#xD;
      continuous exposure is needed. This study will evaluate the combination of continuously&#xD;
      administered CAI with three-weekly paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human&#xD;
      ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for&#xD;
      8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration&#xD;
      causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and&#xD;
      continuous exposure is needed. This study will evaluate the combination of continuously&#xD;
      administered CAI with three-weekly paclitaxel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 3, 1995</start_date>
  <completion_date type="Actual">November 7, 2013</completion_date>
  <primary_completion_date type="Actual">October 15, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">66</enrollment>
  <condition>Ovarian Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        All patients must have biopsy proven, newly diagnosed epithelial ovarian cancer, primary&#xD;
        epithelial fallopian tube cancer, or peritoneal surface carcinoma. Histopathologic&#xD;
        diagnosis must be confirmed in the pathology department of the treating institution prior&#xD;
        to initiation of therapy. Diagnosis will be confirmed in the Laboratory of Pathology,&#xD;
        National Cancer Institute. This confirmation is not necessary prior to entering the patient&#xD;
        onto protocol.&#xD;
&#xD;
        Patients must have FIGO stage III or IV disease and will undergo attempted surgical&#xD;
        debulking prior to the initiation of chemotherapy.&#xD;
&#xD;
        Patients must be able to begin therapy within 6 weeks of staging laparotomy and should have&#xD;
        an indwelling venous access device placed. A double lumen catheter is preferred.&#xD;
&#xD;
        Performance status of less than or equal to ECOG 2.&#xD;
&#xD;
        Patients must be able to give written informed consent and express a willingness to meet&#xD;
        all of the expected requirements of the protocol.&#xD;
&#xD;
        All patients must be registered by calling the Orkand Corporation at 301-402-1732 between&#xD;
        the hours of 8:30 AM and 5:00 PM EST; Eligibility criteria will be queried.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Evidence CNS involvement (patients with normal clinical exam will not require a head CT&#xD;
        scan or MRI).&#xD;
&#xD;
        History of myocardial infarction or unstable dysrhythmia within 1 month of study entry.&#xD;
&#xD;
        Creatinine clearance of less than 60 cc/min, ANC less than 1000/cm3, platelet count less&#xD;
        than 1000,000/cm3.&#xD;
&#xD;
        History of active GI bleeding within the last 30 days.&#xD;
&#xD;
        Prior therapy other than surgery for this malignancy.&#xD;
&#xD;
        Abnormal PT, PTT, and bilirubin. SGOT greater than or equal to 3 times the upper limit of&#xD;
        normal.&#xD;
&#xD;
        Previous history of invasive malignancy.&#xD;
&#xD;
        Patients with ureteral obstruction must have this corrected prior to starting therapy.&#xD;
&#xD;
        Patients with germ cell, mixed Muellerian and borderline histologies are specifically&#xD;
        excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise C Kohn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kohn EC, Sarosy GA, Davis P, Christian M, Link CE, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A, Reed E. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 1996 Aug;62(2):181-91. doi: 10.1006/gyno.1996.0213.</citation>
    <PMID>8751547</PMID>
  </reference>
  <reference>
    <citation>Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol. 1995 Jun;22(3 Suppl 6):90-6.</citation>
    <PMID>7541159</PMID>
  </reference>
  <reference>
    <citation>Link CJ Jr, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E. Cutaneous manifestations of Taxol therapy. Invest New Drugs. 1995;13(3):261-3. doi: 10.1007/BF00873811.</citation>
    <PMID>8729957</PMID>
  </reference>
  <verification_date>November 7, 2013</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Initial Therapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

